For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Sangamo Therapeutics Inc (NASDAQ: SGMO) closed at $0.55 in the last session, down -4.37% from day before closing price of $0.57. In other words, the price has decreased by -$4.37 from its previous closing price. On the day, 5.72 million shares were traded. SGMO stock price reached its highest trading level at $0.5949 during the session, while it also had its lowest trading level at $0.538.
Ratios:
We take a closer look at SGMO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 0.76. In the meantime, Its Debt-to-Equity ratio is 5.07 whereas as Long-Term Debt/Eq ratio is at 5.07.
On December 10, 2024, H.C. Wainwright reiterated its Buy ratingand also kept the price unchanged to $10.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on November 03, 2023, whereas the target price for the stock was revised from $6 to $2.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SGMO now has a Market Capitalization of 133744096 and an Enterprise Value of 126772000. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.10 while its Price-to-Book (P/B) ratio in mrq is 25.03. Its current Enterprise Value per Revenue stands at 1.988 whereas that against EBITDA is -1.693.
Stock Price History:
The Beta on a monthly basis for SGMO is 1.20, which has changed by -0.21428573 over the last 52 weeks, in comparison to a change of 0.16821623 over the same period for the S&P500. Over the past 52 weeks, SGMO has reached a high of $3.18, while it has fallen to a 52-week low of $0.41. The 50-Day Moving Average of the stock is 7.16%, while the 200-Day Moving Average is calculated to be -51.06%.
Shares Statistics:
According to the various share statistics, SGMO traded on average about 5.46M shares per day over the past 3-months and 8039530 shares per day over the past 10 days. A total of 245.40M shares are outstanding, with a floating share count of 237.62M. Insiders hold about 3.17% of the company’s shares, while institutions hold 22.01% stake in the company. Shares short for SGMO as of 1752537600 were 23364456 with a Short Ratio of 4.28, compared to 1749772800 on 25671043. Therefore, it implies a Short% of Shares Outstanding of 23364456 and a Short% of Float of 9.62.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
At present, 2.0 analysts are actively evaluating the performance of Sangamo Therapeutics Inc (SGMO) in the stock market.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.11 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.44 and -$0.54 for the fiscal current year, implying an average EPS of -$0.49. EPS for the following year is -$0.38, with 2.0 analysts recommending between -$0.35 and -$0.4.
Revenue Estimates
According to 5 analysts, the current quarter’s revenue is expected to be $31.68M. It ranges from a high estimate of $100M to a low estimate of $400k. As of the current estimate, Sangamo Therapeutics Inc’s year-ago sales were $356k
A total of 5 analysts have provided revenue estimates for SGMO’s current fiscal year. The highest revenue estimate was $106.4M, while the lowest revenue estimate was $20.8M, resulting in an average revenue estimate of $57.68M. In the same quarter a year ago, actual revenue was $57.8MBased on 5 analysts’ estimates, the company’s revenue will be $50.02M in the next fiscal year. The high estimate is $114.2M and the low estimate is $9.9M.
